Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MORAb-009 plus pemetrexed and cisplatin in unresectable malignant pleural mesothelioma
NL-OMON37190Phase 2Recruiting
- Sponsor
- Morphotek
- Start
- Feb 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of amatuximab in pleural mesothelioma, sponsored by Morphotek. Primary endpoints: Progression-free survival at 6 months, Safety and tolerability and 1 more. Started Feb 2010; status: recruiting.
02
Drugs
amatuximab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON37190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37190.